He then completed a faculty development fellowship at Johns Hopkins University in Baltimore, Maryland. He presently is clinical professor of medicine at Jefferson Medical College and chairman of the Division of Gastroenterology and associate program director of the Department of Medicine at Albert Einstein Medical Center in Philadelphia, Pennsylvania. Dr Katz is a recognized national authority on esophageal disease. His research interests include all aspects of gastroesophageal reflux disease, including nocturnal recovery of gastric acid secretion during proton pump inhibitor therapy and esophageal-pain perception. In spite of his many research and administrative responsibilities, he remains a practicing clinician and dedicated researcher with active teaching and editorial positions in addition to lecturing on many gastroenterology-related topics. Dr Katz is an editorial reviewer for the Annals of Internal Medicine, the American Journal of Gastroenterology, Gastroenterology, and Digestive Diseases and Sciences. He has contributed to the publication of over 150 peer-reviewed papers, as well as numerous abstracts, books, and monographs. His generous contributions of time, effort, and creativity to the College began in 1995 as a member of the Educational Affairs Committee, on which he served as Chair from 1996 to 1999. He has remained an active and loyal member of the College, serving in numerous capacities, including as a member of the board of trustees since 2001. However, perhaps his most important contributions have been inspired by his passion for education and training; in these areas he has spearheaded numerous projects and devoted countless hours of his time, creativity, and hard work. He served as course director of the ACG National Postgraduate Course in 2005 and pioneered the Whats New in GI Pharmacology? course, remaining involved since its inception in 1999. Dr Katz has taken on the challenge of serving as our representative to the American Board of Internal Medicine, working with the ABIM on such important issues as establishing appropriate criteria for gastroenterology training and board recertification. Over the years he has been deeply involved in programs that target GI fellows working to ensure that the clinicians of tomorrow develop a bond with the College. He was a speaker at the ACG Second Year Fellows Conference in 2007 and 2009, served as chair of the North American Conference of Gastroenterology Fellows on behalf of the College from 1995 to 2009, and was involved in the ACG/Astra Merck Senior Fellow Conference from 1992 to 2001. One of Dr Katzs most recent and significant contributions to the College has been his driving force behind the development and launch of the ACG Education Universe, an innovative, online educational portal offering a library of ACG educational activities.
Is Ursodeoxycholic Acid Effective for the Treatment of Primary Sclerosing Cholangitis?
Gastroneterol Hepatol. 2006;2:843-849. 2. Cullen SN, Chapman RW. The medical management of primary sclerosing cholangitis. Semin Liver Dis. 2006;26:52-61. 3. Chen W, Gluud C. Bile acids for primary sclerosing cholangitis (review). Cochrane Database Syst Rev. 2004;3:CD004036. 4. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology. 2001;121:900-907.
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
Finance Finance Search Thu, Sep 12, 2013, 10:54 PM EDT – U.S. Markets closed Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology Press Release: Sucampo Pharmaceuticals, Inc. 3 hours ago 5.69 +0.05 BETHESDA, Md., Sept. 12, 2013 (GLOBE NEWSWIRE) — Sucampo AG (“SAG”), a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. ( SCMP ) (“Sucampo”), announced today that it will present four posters evaluating the overall efficacy and tolerability of AMITIZA(R) (lubiprostone) as a treatment for chronic idiopathic constipation (CIC). These posters contain data demonstrating the efficacy and tolerability of AMITIZA regardless of age, gender, and race, a pooled analysis of the most frequent adverse events associated with AMITIZA, and an evaluation of the efficacy of AMITIZA in patients suffering from refractory constipation. Sucampo will present these data during the Annual Meeting of the Swiss Society of Gastroenterology in Basel, Switzerland on Friday, September 13, 2013. “AMITIZA has been proven to be effective in treating a wide range of patients suffering from CIC,” said Ryuji Ueno, MD, PhD, PhD, SAG’s President and Chief Scientific Officer. “We are excited to present these data on AMITIZA, the world’s first chloride channel activator, to gastroenterologists in Switzerland.” AMITIZA increases intestinal fluid secretion, softens stools and increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with CIC. The following posters will be presented between 1:30-2:00 p.m. CEST (7:30-8:00 a.m. ET) at the Annual Meeting of the Swiss Society of Gastroenterology at the Basel Congress Center in Basel, Switzerland on Friday, September 13, 2013: Long-Term Efficacy of Lubiprostone Demonstrated in Patients with Constipation Regardless of Age, Gender or Race Taryn R.